The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1644
ISSUE1644
February 21, 2022
Tezepelumab (Tezspire) for Severe Asthma
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Tezepelumab (Tezspire) for Severe Asthma
February 21, 2022 (Issue: 1644)
Tezepelumab-ekko (Tezspire – AstraZeneca/Amgen),
a subcutaneously administered thymic stromal
lymphopoietin (TSLP) blocker, has been approved
by the FDA for add-on maintenance treatment of
severe asthma in patients ≥12 years old. It is the...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.